Roche posts rise in profit in 2010
Swiss pharmaceutical group Roche has reported a four per cent increase in full-year net profit to SFr8.89 billion ($9.52 billion) in 2010.
Growth in sales of Roche's anti-cancer drugs was unable to compensate for a drop in sales of the group’s Tamiflu treatment and the surge in the Swiss franc. Full-year sales fell by three per cent to SFr47.47 billion, according to figures published on Wednesday.
Commenting on the Basel-based group’s performance, CEO Severin Schwan said the results were “solid despite an increasingly challenging market environment”.
Roche said it expects healthcare reforms in the United States and European austerity measures to dampen growth in 2011.
The group is hoping to save SFr1.8 billion in 2011 through a restructuring plan announced in November.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at email@example.com.